Novo Nordisk

2024 - 12 - 20

CagriSema -- Eli Lilly -- Novo -- Ozempic -- eli lilly stock -- novo aktie -- novo nordisk stock -- novo stock CagriSema - Eli Lilly - Novo - Ozempic - eli lilly stock - novo aktie - novo nordisk stock - novo stock

Post cover
Image courtesy of "STAT"

Next-gen obesity treatment from Novo Nordisk misses mark in ... (STAT)

The drug, called CagriSema, helped patients lose substantial weight, but not as much as the company had forecasted.

Post cover
Image courtesy of "CNBC"

Novo Nordisk shares plunge 19% after disappointing trial results ... (CNBC)

Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point on Friday after reporting trial results that missed expectations.

Post cover
Image courtesy of "Reuters"

Novo Nordisk shares plunge after CagriSema obesity drug trial ... (Reuters)

Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped patients cut their weight by 22.7% in a late-stage trial, ...

Post cover
Image courtesy of "GlobeNewswire"

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in ... (GlobeNewswire)

Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme....

Post cover
Image courtesy of "Financial Times"

Novo Nordisk shares tumble as weight-loss drug trial data disappoints (Financial Times)

Obesity drug CagriSema misses goal of 25% body weight reduction.

Post cover
Image courtesy of "Barron's"

Novo Nordisk Stock Crashes More Than 20% After Disappointing ... (Barron's)

Novo Nordisk stock fell sharply after the Ozempic maker's experimental obesity drug CagriSema disappointed investors. Eli Lilly Shares Soar.

Post cover
Image courtesy of "The Wall Street Journal"

Novo Nordisk Shares Plunge After New Obesity Shot Falls Short of ... (The Wall Street Journal)

Danish pharmecutical company loses $100 billion in market value after study results disappoints.

Post cover
Image courtesy of "CNN"

Novo Nordisk's next-generation weight-loss drug matches Lilly's ... (CNN)

Novo Nordisk's latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly's currently approved medicine, Zepbound, ...

Post cover
Image courtesy of "BioSpace"

Novo Nosedives on Underwhelming CagriSema Phase III Weight ... (BioSpace)

Investors appeared disappointed by CagriSema's Phase III readout, which showed weight loss that fell short of Novo Nordisk's prior projections for the ...

Post cover
Image courtesy of "Investor's Business Daily"

Novo Nordisk Dives On CagriSegma Obesity Drug Trial (Investor's Business Daily)

Novo Nordisk stock crashed Friday after the Danish giant's experimental obesity drug CagriSegma missed goals. Eli Lilly and Viking jumped.

Post cover
Image courtesy of "GlobeNewswire"

Novo Nordisk A/S - share repurchase programme (GlobeNewswire)

Bagsværd, Denmark, 20 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation...

Post cover
Image courtesy of "FierceBiotech"

Novo stock crashes after CagriSema misses weight-loss goal (FierceBiotech)

A phase 3 trial of Novo Nordisk's next-generation obesity prospect CagriSema has failed to achieve the level of weight loss targeted by executives, ...

Explore the last week